BBioMarin Pharmaceutical focuses on developing and selling medicines for people with rare genetic diseases. It creates orphan drugs—therapies designed for small patient populations—and has a lineup of approved treatments such as Vimizim (enzyme replacement for Morquio A syndrome), Naglazyme (enzyme replacement for MPS VI), and Kuvan (a cofactor therapy for phenylketonuria). The company’s products work by supplying missing or defective enzymes or cofactors in patients’ bodies, helping to treat the underlying metabolic problems. BioMarin differentiates itself through its specialization in rare diseases, building a pipeline of product candidates across stages of development and selling primarily to specialty pharmacies and hospitals. Its goal is to provide approved, accessible treatments for patients with limited options and to grow its portfolio to cover more rare genetic conditions.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Rafael, CA
Founded
1997
See people who can refer or advise you
Total Funding
$1.9B
Above
Industry Average
Funded Over
9 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Rafael, CA
Founded
1997
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs